Barclays Raises Hims & Hers Target After Novo Deal Clears
Barclays boosts its target on Hims & Hers Health as Novo Nordisk deal removes a key legal overhang, while Progyny see...
Learn where ETF fee disclosures for Dividend Aristocrats are published online, and how to interpret expense data to compare options.
13,212 articlesBarclays boosts its target on Hims & Hers Health as Novo Nordisk deal removes a key legal overhang, while Progyny see...
When a mid-size fund dumps a sizable stake, it sends a signal about risk and opportunity. Kadensa Capital liquidates ...
A sharp 87% drop in February crypto losses belies a pivot by attackers toward social engineering and user-targeted sc...
A January 2026 FHFA release details a two-score, lender-choice framework that could ripple through mortgage pricing, ...
Aster Chain today unveiled its mainnet, promising default privacy and CEX-like performance for DeFi traders. The laun...
Insider trades can hint at a company's future, but not every move is meaningful. This article shows how to filter sig...
Uber's move to back Rivian could reshape both companies' futures and the EV/autonomy landscape. This guide breaks dow...
Prentice Capital has exited its Compass position, reporting a zero stake after the latest quarter. This move highligh...
A major crypto development is sending ripples through the market as Ethereum reacts to optimistic signals from Iran a...
Lucid Group stock down has turned a lot of eyes toward a bold question: should investors jump in now or wait? This ar...
A New Mexico verdict against Meta and a California ruling involving Meta and YouTube mark a turning point in lawsuits...
A major sports policy change bars transgender women from competing in women's events. This decision carries far more ...